NTO-1151

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameNTO-1151
Drug Alias NameTriapinePAN-811OCX-1913-APNTO-1151 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibonucleotide reductase inhibitors
TargetsRibonucleotide reductase
Therapy Area/IndicationsChronic eosinophilic leukemia (CEL)Esophageal adenocarcinomaGastroenteropancreatic neuroendocrine tumor +[62] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNanotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteNorthwestern University
Inactive CompaniesVion Pharmaceuticals IncUniversity Health Network (Uhn)
Active IndicationsGastroenteropancreatic neuroendocrine tumorVaginal NeoplasmsUterine Cervical Neoplasms +[10] 
Inactive IndicationsChronic eosinophilic leukemia (CEL)Esophageal adenocarcinomaSolid tumours +[52] 

Other Information

ATC CodeN/A
Related LinksN/A